Table 3 Tumor regression in the intent-to-treat population

From: Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)

 

ICT group (n = 52)

CRT group (n = 52)

pCR, n (%) (95% CIa)

17 (32.7) (20.33, 47.11)

18 (34.6) (21.97, 49.09)

Ratio of pCR rates (90% CIb)

0.94 (0.60, 1.49)

 

MPR, n (%) (95% CIa)

22 (42.3) (28.73, 56.80)

30 (57.7) (43.20, 71.27)

Tumor regression score, n (%)c

Grade1a

17 (32.7)

18 (34.6)

Grade1b

5 (9.6)

12 (23.1)

Grade2

7 (13.5)

7 (13.5)

Grade3

16 (30.8)

2 (3.8)

  1. ICT, neoadjuvant immunochemotherapy; CRT, neoadjuvant chemoradiotherapy.
  2. a95% CI of rate was calculated by the Clopper-pearson method.
  3. b90% CI of ratio of pCR rates was calculated by the Wald method.
  4. cTumor regression score was assessed according to Becker criteria.
Back to article page